acricept Did anyone notice the article in Fin Rev during the week summarising an article in the Lancet (UK medical journal). A long term study has found the largest? selling drug for alzheimers, Aricept? is next to useless. These findings were at odds with the drug companies studies.
It leaves plenty of room in the market for PBT but is a blow to anyone with the the disease.
PBT looks like it is trending down. It is clearly announcement driven and from past announcements it will be a few months away (sometime before year end) before they announce the start of the phase 1 trial for pbt2.
question for stolwyk, page-9
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $1.937K | 645.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 77 | 96988980 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 655773 | 2 |
View Market Depth
| Last trade - 10.00am 15/11/2024 (20 minute delay) ? |
| ATH (ASX) Chart |